| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Black Diamond Therapeutics, Inc. (BDTX) has 6 insiders with recent SEC Form 4 filings, including 14 buys and 11 sells. BDTX is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Dir | 93.6K | $267.6K | - | |
| Dir | 37.1K | $106.2K | - | |
| Dir | 30.6K | $87.4K | - | |
| Dir | 30.6K | $87.4K | - | |
| Dir | 30.6K | $87.4K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Sep 14, 2020 | Leggett Thomas | Chief Financial Officer | Sale+OE | 3,000 | $31.00 | $93,000.00 | -100% | |
| Sep 3, 2020 | Roberts Christopher D. | Chief Scientific Officer | Sale+OE | 2,500 | $29.59 | $73,987.40 | -51.5% | |
| Aug 11, 2020 | Bolzon Bradley J Phd75 | Director, 10% Owner | Sell | 13,792 | $33.06 | $455,989.34 | - | |
| Aug 11, 2020 | Versant Venture Capital Vi, L.P.64 | 10% Owner | Sell | 13,792 | $33.06 | $455,989.34 | - | |
| Feb 3, 2020 | Flynn James E62 | 10% Owner, Possible Member Of 10% Group | Buy | 400,000 | $19.00 | $7,600,000.00 | +105.6% | |
| Feb 3, 2020 | Shah Rajeev M. | Director | Buy | 1,000,000 | $19.00 | $19,000,000.00 | +62.9% | |
| Feb 3, 2020 | Versant Venture Capital Vi, L.P.64 | 10% Owner | Buy | 894,736 | $19.00 | $16,999,984.00 | +9.0% | |
| Feb 3, 2020 | Bolzon Bradley J Phd75 | Director | Buy | 894,736 | $19.00 | $16,999,984.00 | +9.0% | |
| Feb 3, 2020 | Hatzis-Schoch Brent82 | See Remarks | Buy | 3,000 | $19.00 | $57,000.00 | New | |
| Feb 3, 2020 | Behbahani Ali46 | Director | Buy | 800,000 | $19.00 | $15,200,000.00 | +30.2% |